主页
市场
图表与思路
Algo
新闻
Store
经纪商
下载
经济日历
交易信号
网页端
键入
/
进行搜索:@user,$symbol
查找
登录
创建账户
中文
English
Русский
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
AVBP
#2111
ArriVent BioPharma, Inc. Common Stock
22.9
7
+0.22%
版块:
基础:
利润货币:
日范围
年范围
日变化
+0.22%
每月变动
-1.20%
6个月变化
+19.57%
年变化
-4.01%
前一天收盘价
22.9
2
Open
22.9
3
Bid
Ask
Low
22.9
3
High
22.9
7
交易量
76
市场
股票
医疗保健
AVBP
Open full chart
Financials
Overview
声明
Statistics
Dividends
Quarterly
Annual
Value
2024
TTM
Key stats
Total common shares outstanding
34.02 M
—
Valuation ratios
Enterprise value
831.9 M
2.83 B
Price to earnings ratio
-10.41
-25.11
Price to sales ratio
—
—
Price to cash flow ratio
11.94
27.39
Price to book ratio
3.25
5.23
Enterprise value to EBITDA ratio
—
—
Profitability ratios
Return on assets %
0.29
0.6
Return on equity %
0.31
0.64
Return on invested capital %
962.92
—
Gross margin %
—
—
Operating margin %
—
—
EBITDA margin %
—
—
Net margin %
—
—
Liquidity ratios
Quick ratio
—
—
Current ratio
13.14
55.12
Inventory turnover
—
—
Asset turnover
—
—
Solvency ratios
Debt to assets ratio
—
—
Debt to equity ratio
—
—
Long term debt to total assets ratio
—
—
Long term debt to total equity ratio
—
—
Per share metrics
Operating cash flow per share
2.23
4.12
EBIT per share
—
—
EBITDA per share
—
—
Total debt per share
—
—
Cash per share
6.95
21.45
Net current asset value per share
7.21
27.5
Tangible book value per share
8.19
28.58
Working capital per share
6.66
25.5
Book value per share
8.19
28.58
新闻
Cantor Fitzgerald重申ArriVent股票评级为"增持"
ArriVent stock rating reiterated as Overweight by Cantor Fitzgerald
Oppenheimer维持ArriVent BioPharma股票"跑赢大盘"评级
Oppenheimer reiterates Outperform rating on ArriVent BioPharma stock
ArriVent BioPharma (AVBP): Its Leading Asset, Furmonertinib, Supports A Cautious Buy
ArriVent BioPharma: A De-Risked Binary With Near-Term Catalysts (NASDAQ:AVBP)
Cantor Fitzgerald 给予ArriVent BioPharma股票"增持"评级
Cantor Fitzgerald initiates ArriVent BioPharma stock with Overweight rating
ArriVent doses first patient in pivotal phase 3 trial for lung cancer drug
BTIG给ArriVent BioPharma股票首次评级为"买入",看好其肿瘤治疗潜力
ArriVent BioPharma stock initiated with Buy rating at BTIG on oncology potential
Truist证券给予ArriVent BioPharma买入评级,看好其肺癌药物前景